What impact will RM25 million have on haemophilia care in Malaysia?

Question

Accepted Answer

RM25 Million Allocation Expected to Enhance Haemophilia Care in Malaysia

The increased RM25 million allocation for rare disease treatment costs in the 2025 Budget is anticipated to significantly improve haemophilia care in Malaysia. This funding aims to alleviate the substantial financial burden faced by families managing the high costs associated with treating haemophilia, a condition affecting approximately one in every 30,000 Malaysians. The allocation is intended to ensure that these essential treatments reach those in need and are distributed equitably based on individual patient requirements.
Improved Access to Cost-Effective Treatments

The enhanced budget is expected to facilitate greater access to treatments for haemophilia patients. Currently, the majority of patients rely on plasma-based treatments, which are not only more expensive but also necessitate frequent injections three times a week. The introduction of more cost-effective options, such as Emicizumab, could represent a substantial improvement in care management and patient well-being.
Potential of Emicizumab as a Treatment Option

The Haemophilia Society of Malaysia (HSM) has proposed that the Ministry of Health (MOH) explore Emicizumab as a viable treatment, particularly for children under eight years old and individuals experiencing inhibitor complications. This medication requires a single subcutaneous injection every four weeks, which contrasts with the current regimen's frequency and method. For paediatric patients, the dosage is weight-based, potentially leading to lower overall treatment costs for the MOH.
Reducing Treatment Burden and Costs

Beyond the financial implications, the shift towards treatments like Emicizumab could also reduce the physical burden on patients. Unlike traditional factor concentrate treatments that are administered intravenously, Emicizumab is an under-the-skin injection. This method is generally perceived as less painful and more convenient for patients, especially children, potentially leading to better adherence to treatment plans and improved quality of life.
Collaboration and Patient-Centric Decision-Making

The HSM has expressed a desire for continued engagement with the MOH to ensure that treatment decisions are informed by patient-specific outcomes and the experiences of the rare disease community. By involving patient advocacy groups in the evaluation of new therapeutic options, the Ministry can better align treatment strategies with the practical needs and long-term well-being of individuals living with haemophilia. This collaborative approach is seen as crucial for optimising the impact of the allocated funds.

Reading history

Hide →

This history is cleared when the page is closed.

What impact will RM25 million have on haemophilia care in Malaysia?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

3

0

0

Share with friends